Cohort Event Monitoring Study of Pyramax®

Inclusion Criteria: * Uncomplicated malaria (Plasmodia of any species) diagnosed as per national policies and in line with WHO recommendations: * Fever or history of fever in the previous 24 h and/or the presence of anaemia, for which pallor of the palms appears to be the most reliable sign in young children. * Confirmation of malaria by a parasitological diagnosis (RDT or Microscopy (thick blood smear). analysis). * Weight ≥5 kg - \< 20 kg (granules); ≥20 kg (tablets). * Ability to take an oral medication. * Ability and willingness to participate based on signed informed consent (a parent or a guardian has to sign for children below 18 years old) and on signed assent form for minors that could be required per national regulations in each participating country. * The patient has to comply with all scheduled follow-up visits. Exclusion Criteria: * Patients with clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage 3 or 4). * Known allergy to artemisinin and/or to pyronaridine. * Known pregnancy. * Lactating women should be excluded if other anti-malarial treatments are available. * Complicated malaria as per WHO definition (Annex 2) * Patients that the investigator considers would be at particular risk if receiving an anti-malarial or if participating in the study. * Patients having been treated with Pyramax in the previous 28 days.